A Phase 2 interventional study of Paracetamol and Ibuprofen in Ductus Arteriosus, Patent, sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A. Completed at 5 sites in Italy. Open to participants aged 25 Weeks to 31 Weeks. Per ClinicalTrials.gov, last updated 2019-07-12.
Sponsored by Aziende Chimiche Riunite Angelini Francesco S.p.A · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing acetaminophen in Ductus Arteriosus, Patent — 4 open to participants now, 4 under way, 1 of them phase 3. Acetaminophen · Ductus Arteriosus, Patent.
Among the 24 studies testing acetaminophen in Ductus Arteriosus, Patent, this one is the 7th largest by enrollment, is one of 2 that started in 2015, is one of 8 in phase 2, and was the 8th registered.
146 studies on the registry are indexed under Ductus Arteriosus, Patent; 21 are open to participants now.
Browse Ductus Arteriosus, Patent studies →4 of the 24 studies testing acetaminophen in Ductus Arteriosus, Patent are open now, in 5 countries. Recruiting first, the newest first:
Mount Sinai Hospital, Canada · Sites in Australia, Canada, Hong Kong and 1 more country
Ages up to 27 wk
Manchester University NHS Foundation Trust · Sites in United Kingdom
Ages 23 wk–32 wk
Soha mahmoud Hussien mahdy
Ages 1 days–28 days · Healthy volunteers
Assiut University
Ages 28 wk–37 wk · Healthy volunteers
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 14 Ductus Arteriosus, Patent studies recruiting now, 4 (29%) set no upper age limit and 10 (71%) stop at 75 or younger; 14 take children under 18; 1 takes healthy volunteers.
This study: 25 Weeks to 31 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 7 · Phase 4 3
First in 2012; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 110 is above the median of 80 across 80 interventional studies indexed under Ductus Arteriosus, Patent.
Median enrollment 68 across the 24 interventional studies. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Aziende Chimiche Riunite Angelini Francesco S.p.A, one of the names counted as Angelini Pharma. Under that name alone:
Aziende Chimiche Riunite Angelini Francesco S.p.A is the lead sponsor of 40 studies on the registry; 1 is open to participants now.
Angelini Pharma has 1 study filed under Ductus Arteriosus, Patent — fewer than ten, so there is no comparison to draw.
1 of the studies testing acetaminophen in Ductus Arteriosus, Patent that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05340582Mount Sinai Hospital, CanadaCo-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing acetaminophen in Ductus Arteriosus, Patent, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the efficacy and safety of paracetamol in comparison to ibuprofen in the treatment of patent ductus arteriosus (PDA) in preterm infants.
Although patency of the ductus arteriosus is essential for fetal circulation, the postnatal ductal closure is critical for postnatal circulatory adaptation. In premature infants the circulating prostaglandin levels are higher than at term, and respiratory difficulties may lead to a state of hypoxia, which contribute to the failure of the ductus closure. Recently, an incidental finding in one preterm infant led to look at paracetamol, one of the most common drugs available, as an alternative therapeutic approach to ductal closure. If paracetamol is proven to be effective, it could become the treatment of choice for the management of PDA, mainly due to its more favorable safety profile.
Although the recent results available in the literature demonstrates an highly success rate in ductal closure with paracetamol, all case studies are not powered to show efficacy of paracetamol for PDA closure. Further prospective randomized-controlled trials are needed to evaluate the efficacy of paracetamol versus ibuprofen for the closure of PDA.
If paracetamol is indeed proven to be effective, it could become the treatment of choice for the management of PDA, mainly due to its more favorable side effect profile. In order to test this hypothesis, a randomized, open label, parallel groups, comparator controlled, multicentre, prospective study is proposed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Echocardiographic evidence of hemodynamically significant patent ductus arteriosus at the first 24-72 hours of life.
The diagnosis of hemodynamically significant PDA requiring treatment will be made by echocardiographic demonstration of a ductal left-to-right shunt, with a left atrium-to-aortic root ratio >1.3 or a ductal size >1.5 mm and excluding the cases in which the closing flow pattern suggests a restrictive PDA.
Exclusion Criteria:
Severe liver failure, defined as elevated liver enzymes (/Glutamate-Pyruvate Transaminase and Aspartate aminotransferase/GOT) > 2 times the upper boundary of the normal range. For this kind of population the following normal ranges will be considered [Rosenthal, 1997]:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paracetamol intravenous solution 15 mg/kg (corresponding to 1.5 ml/kg) per dose every 6 hours for 3 days, for a total amount of 12 doses.
Drug: Paracetamol
Ibuprofen intravenous solution at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 5 mg/kg at 48 h.
Drug: Ibuprofen
Also known as: Acetaminophen
success rate in closing PDA using paracetamol in comparison to ibuprofen.
assessed echocardiographically.
Time frame: at Visit 3 (day 3).
number of re-openings.
assessed echocardiographically.
Time frame: at Follow-up 3 (day 30).
success rate in closing PDA after the second treatment course of ibuprofen as rescue medication.
assessed echocardiographically.
Time frame: at Visit 6 (day 6).
success rate of closing PDA after the first day of the first treatment course.
assessed echocardiographically.
Time frame: at Visit 1 (day 1).
success rate of closing PDA after the second day of the first treatment course.
assessed echocardiographically.
Time frame: at Visit 2 (day 2).
incidence of surgical ligation.
Time frame: at Follow-up 3 (day 30).
incidence of renal failure, liver failure and gastrointestinal complications (including isolated intestinal perforation).
assessed by laboratory analysis.
Time frame: at Follow-up 3 (day 30).
incidence of death,
Time frame: at Follow-up 3 (day 30).
incidence of death.
Time frame: at Follow-up 4 (40 weeks post-conception).
incidence of sepsis.
Time frame: at Follow-up 3 (day 30).
hospital-stay duration in Neonatal Intensive Care Unit.
Time frame: at Follow-up 4 (40 weeks post-conception).
occurrence of adverse effects.
Time frame: at Follow-up 3 (day 30).
Ran from Dec 2015 to primary completion in Jan 2019, 37 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acetaminophen
Aziende Chimiche Riunite Angelini Francesco S.p.A →